Difference between revisions of "Light-chain (AL) amyloidosis - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://www.amjmed.com/article/0002-9343(85)90521-2" to "https://doi.org/10.1016/0002-9343(85)90521-2") |
m |
||
| Line 1: | Line 1: | ||
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? Please go to the [[Light-chain (AL) amyloidosis|main light-chain (AL) amyloidosis regimen page]] to find other regimens. | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? Please go to the [[Light-chain (AL) amyloidosis|main light-chain (AL) amyloidosis regimen page]] to find other regimens. | ||
| − | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
| Line 6: | Line 5: | ||
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | ||
|} | |} | ||
| − | |||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=First-line therapy (including transplant ineligible)= | =First-line therapy (including transplant ineligible)= | ||
==Colchicine monotherapy {{#subobject:06983b|Regimen=1}}== | ==Colchicine monotherapy {{#subobject:06983b|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:9ee4f6|Variant=1}}=== | ===Regimen {{#subobject:9ee4f6|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| Line 41: | Line 39: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Colchicine (Colcrys)]] | *[[Colchicine (Colcrys)]] | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. [https://doi.org/10.1016/0002-9343(85)90521-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3934968 PubMed] | # Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. [https://doi.org/10.1016/0002-9343(85)90521-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3934968 PubMed] | ||
# Cohen AS, Rubinow A, Anderson JJ, Skinner M, Mason JH, Libbey C, Kayne H. Survival of patients with primary (AL) amyloidosis: colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med. 1987 Jun;82(6):1182-90. [https://www.amjmed.com/article/0002-9343(87)90222-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3605135 PubMed] | # Cohen AS, Rubinow A, Anderson JJ, Skinner M, Mason JH, Libbey C, Kayne H. Survival of patients with primary (AL) amyloidosis: colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med. 1987 Jun;82(6):1182-90. [https://www.amjmed.com/article/0002-9343(87)90222-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3605135 PubMed] | ||
# Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. [https://doi.org/10.1056/NEJM199704243361702 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9110907 PubMed] | # Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. [https://doi.org/10.1056/NEJM199704243361702 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9110907 PubMed] | ||
| − | |||
==Melphalan & Prednisone (MP) {{#subobject:946da1|Regimen=1}}== | ==Melphalan & Prednisone (MP) {{#subobject:946da1|Regimen=1}}== | ||
| − | |||
MP: '''<u>M</u>'''elphalan & '''<u>P</u>'''rednisone | MP: '''<u>M</u>'''elphalan & '''<u>P</u>'''rednisone | ||
| + | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:b1471a|Variant=1}}=== | ===Regimen {{#subobject:b1471a|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| Line 82: | Line 80: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Melphalan (Alkeran)]] | *[[Melphalan (Alkeran)]] | ||
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
*[[Prednisone (Sterapred)]] | *[[Prednisone (Sterapred)]] | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978 Oct;52(4):818-27. [http://www.bloodjournal.org/content/52/4/818.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/356916 PubMed] | # Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978 Oct;52(4):818-27. [http://www.bloodjournal.org/content/52/4/818.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/356916 PubMed] | ||
# Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. [https://doi.org/10.1016/0002-9343(85)90521-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3934968 PubMed] | # Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. [https://doi.org/10.1016/0002-9343(85)90521-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3934968 PubMed] | ||
# Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. [https://doi.org/10.1056/NEJM199704243361702 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9110907 PubMed] | # Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. [https://doi.org/10.1056/NEJM199704243361702 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9110907 PubMed] | ||
| − | |||
[[Category:Light-chain (AL) amyloidosis regimens]] | [[Category:Light-chain (AL) amyloidosis regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Plasma cell dyscrasias]] | [[Category:Plasma cell dyscrasias]] | ||
[[Category:Historical regimens]] | [[Category:Historical regimens]] | ||
Revision as of 12:02, 1 March 2023
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? Please go to the main light-chain (AL) amyloidosis regimen page to find other regimens.
2 regimens on this page
2 variants on this page
|
First-line therapy (including transplant ineligible)
Colchicine monotherapy
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Kyle et al. 1985 | NR | Randomized (E-switch-ooc) | MP | Seems not superior |
| Cohen et al. 1987 | 1976-1983 | Non-randomized | ||
| Kyle et al. 1997 | 1982-1992 | Phase 3 (C) | 1. MP | Inferior OS |
| 2. Melphalan, Prednisone, Colchicine | Inferior OS |
Chemotherapy
References
- Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. link to original article PubMed
- Cohen AS, Rubinow A, Anderson JJ, Skinner M, Mason JH, Libbey C, Kayne H. Survival of patients with primary (AL) amyloidosis: colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med. 1987 Jun;82(6):1182-90. link to original article PubMed
- Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. link to original article PubMed
Melphalan & Prednisone (MP)
MP: Melphalan & Prednisone
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Kyle et al. 1978 | NR | Randomized (E-esc) | Placebo | Longer time on treatment |
| Kyle et al. 1985 | NR | Randomized (E-switch-ooc) | Colchicine | Seems not superior |
| Kyle et al. 1997 | 1982-1992 | Phase 3 (C) | 1. Colchicine | Superior OS |
| 2. Melphalan, Prednisone, Colchicine | Seems not superior |
References
- Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978 Oct;52(4):818-27. link to original article PubMed
- Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. link to original article PubMed
- Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. link to original article PubMed